Supercomputer simulations have revealed how changes in the shape of the HIV-1 capsid protein may help the virus squeeze its inner core into the host cell's nuclear membrane. The findings, by a ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
Though capsid proteins can assemble around various RNA lengths or even nanoparticles, our study focused on how a long RNA strand first creates a disordered protein-RNA complex that ultimately forms a ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it. More than 40 million people worldwide live with AIDS because of this virus, ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results